April 26, 2011

Sanofi-aventis and Regeneron Report Positive Phase III Results with ZALTRAP® (aflibercept) in Second-line Metastatic Colorectal Cancer

 

Sanofi-aventis and Regeneron Report Positive Phase III Results with ZALTRAP® (aflibercept) in Second-line Metastatic Colorectal Cancer

Paris, France and Tarrytown, NY – April 26, 2011 – Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that the Phase III VELOUR trial evaluating the investigational agent ZALTRAP® (aflibercept), also known as VEGF Trap, in combination with the FOLFIRI chemotherapy regimen [folinic acid (leucovorin), 5-fluorouracil, and irinotecan] versus a regimen of FOLFIRI plus placebo met its primary endpoint of improving overall survival (OS) in the second-line treatment of metastatic colorectal cancer (mCRC)